Duarte, CANCT07544992Now EnrollingIRB Ready

Recurrent Astrocytoma, IDH-Mutant, Grade 4 Clinical Trial in Duarte, CA

Access cutting-edge recurrent astrocytoma, idh-mutant, grade 4 treatment through this phase 1 clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.

Sponsored by City of Hope Medical Center

Quick Self-Assessment

See if you qualify for this Duarte location

Preparing your pre-screening questions…

Expert Care in Duarte

Access recurrent astrocytoma, idh-mutant, grade 4 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent astrocytoma, idh-mutant, grade 4 treatment provided free

Apply for This Duarte Location

Check if you qualify for this recurrent astrocytoma, idh-mutant, grade 4 clinical trial in Duarte, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Duarte

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Duarte site if eligible
  4. 4Begin participation

About This Recurrent Astrocytoma, IDH-Mutant, Grade 4 Study in Duarte

This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients with high-grade gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). EGFR/IL13Rα2 pool-CAR T cells are a type of CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.

Sponsor: City of Hope Medical Center

Who Can Participate

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative.
Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with Study PI approval.
Age 18 years and older.
KPS ≥ 70%, ECOG ≤ 2 (Appendix A).
Life expectancy ≥ 4 weeks.
Participant has a prior histologically confirmed diagnosis of a glioblastoma (IDH-wildtype) or grade 4 IDH-mutant astrocytoma, or has a prior histologically confirmed diagnosis of a grade 2 or 3 astrocytoma and now has radiographic progression consistent with grade 4 IDH-mutant astrocytoma.
Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy (such as temozolomide with or without Optune device), and ≥ 12 weeks after completion of front-line radiation therapy.
COH Clinical Pathology assessment at the initial tumor presentation or recurrent disease (reference Appendix B):
IL13Rα2+ expression by IHC \> 20, and
EGFR gene-altered by NGS or FISH analysis
No known contraindications to leukapheresis, steroids, imaging studies, or tocilizumab.
WBC \> 2000 /dl (or ANC ≥ 1,000/mm3)
Platelets ≥ 75,000/mm3
Hemoglobin \> 9g/dL
Total bilirubin ≤ 1.5x ULN
AST ≤ 2.5x ULN
ALT ≤ 2.5x ULN
Serum creatinine ≤1.6 mg/dL
O2 saturation ≥ 95% on room air.
Seronegative for HIV Ag/Ab combo, HCV, and active HBV
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test.
Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CAR T cells. Main

Exclusion Criteria

Owing to higher frequency of wound-related complications, participants who require active bevacizumab therapy at the time of enrollment are excluded.
Participant has not yet recovered from toxicities of prior therapy.
Participant has received any live vaccine within 30 days prior to enrollment.
Uncontrolled seizure activity and/or clinically evident progressive encephalopathy.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
Clinically significant uncontrolled illness.
Active autoimmune disease requiring systemic immunosuppressive therapy
Active infection requiring IV antibiotics (for example, minor scalp infection is not exclusion).
Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.
Other active malignancy.
Females only: Pregnant or breastfeeding.
Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.
Prospective participants who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Duarte?

Yes, this clinical trial (NCT07544992) has an active research site in Duarte, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Astrocytoma, IDH-Mutant, Grade 4 Treatment Options in Duarte, CA

If you're searching for recurrent astrocytoma, idh-mutant, grade 4 treatment options in Duarte, CA, this clinical trial (NCT07544992) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Duarte research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced recurrent astrocytoma, idh-mutant, grade 4 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent astrocytoma, idh-mutant, grade 4 clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Duarte, CA

See all brain cancer clinical trials recruiting in Duarte — not just this study.

Browse Brain Cancer Trials in Duarte →

Browse More Trials by Condition

Brain Cancer TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Duarte?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Duarte, CA